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Introduction: Benign prostate hyperplasia is one of the most common diseases and a common cause 
of lower urinary tract symptoms in aging men. Various disease management approaches to optimize the 
patient’s long life and efficient status where patient adherence to the prescribed treatment plays a vital 
role. This study evaluated the medication adherence pattern of the patients to obtain successful treatment 
outcomes. Methods: A cross-sectional study was conducted in out-patient department of urology in a tertiary 
care hospital. Patients diagnosed with benign prostate hyperplasia were interviewed using a structured 
questionnaire. Results: The high expenses of medicine, fear of medication, lack of symptomatic relief were 
factors that showed statistically significant (p < 0.05) difference between adherent and non-adherent group. 
Similarly, the duration of diagnosis of the adherent group was significantly less than the non-adherent group 
including the pattern of physical activities (p < 0.05). Adherent group also had more participants working 
in business and services occupation compared to the non-adherent group. Conclusion: The general attitude 
(such as fear of medication and lack of symptomatic relief) is seen as major factors that affect adherent 
pattern in benign prostate hyperplasia patients. These issues can be solved using proper guidance. However, 
the cost of medicines also posts an immense issue for the non-adherent group.
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INTRODUCTION: 
 Benign Prostatic Hyperplasia (BPH) is a 
proliferation of prostatic stromal cells leading to 
prostatic enlargement and bladder outlet obstruction, 
increasing bladder pressure, and reducing urine 
flow.[1] It is the most common disease in older age 
men (approximately 80% after 80 years of age).[2,3] 
Lower Urinary Tract Symptoms (LUTS) is highly 
prevalent among patients with BPH.[2] These 
symptoms negatively impact men’s quality of life 
leading to sleep disturbances, sexual dysfunction, 
and reduced sexual satisfaction.[4]
 Pharmacological drugs such as alpha-
blockers and 5α reductase inhibitors (5-ARI), 
antimuscarinics, phosphodiesterase-5 inhibitors 
(PDE-5) are used for long term treatment of LUTS.
[5,6,7] Despite the effectiveness of the drugs, 
adherence to the treatment is also vital to treatment 
of this disease. Poor adherence attenuates optimum 
clinical benefits and therefore reduces the overall 
effectiveness of health systems.[8,9] However, this 
still remains a challenge due to different factors.[5] 
 In Nepal, there is a lack of studies measuring 
adherence to this medication. In this study, we 
measured the factors affecting adherence for LUTS 
medication among BPH patients attending Dhulikhel 
Hospital.
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METHODS:
 A cross-sectional study was carried out in 
the Department of Urology, Kathmandu University 
Hospital, Dhulikhel Hospital, Kavre from June 2018 
to December 2018 for a duration of six months 
after obtaining ethical clearance from Institutional 
Review Committee, Kathmandu University School 
of Medical Sciences (IRC approval No. 49/18). An 
approval, to conduct study, was also taken from the 
Urology Department. 
 The inclusion criteria for participants were 
their attendance to out-patient department in the 
Department of Urology, Dhulikhel Hospital. They 
had to be diagnosed with BPH for a duration of 
greater than or equal to six months. They also needed 
to agree for participation in the study by giving 
written consent. Participants were excluded if they 
refused to participate or were newly diagnosed with 
BPH or under medications for less than six months 
duration.
 Using the CIA factbook, the male population 
within vulnerable age group (>24 years) for BPH 
was found to be 20%.[11] With this, confidence 
level of 95% and margin of error 8.5% was used to 
calculate the sample size of 86.
 Random days of the week were selected in 
the study period to collect the data. Urology out-
patient department (OPD) provided treatment for 
three days in a week i.e. on Monday, Wednesday and 
Friday. Initial two random days of the week were 
selected to collect the data; the random days being 
Monday and Wednesday. These two days were the 
same throughout the study period. The participants 
were chosen by using convenient sampling technique 
on those random days of the week.  A pilot study 
of the questionnaire was done for 10 participants 
for possible modifications to make questionnaire 
understandable, convenient to ask to patients and 
reduce bias in answers. These 10 participants were 
also selected on same random days of the week and by 
using convenient sampling technique. However, no 
modification was required and those 10 participants 
were also included in the final analysis. 
 The structured questionnaire consisted of 
general information and factors related to adherence. 
General information of patients included age, 
marital status, literacy, ethnicity and occupation 
along with their lifestyle choices such as alcohol 
consumption, smoking, physical activities and 
duration of diagnosis. Factors such as perception 
about medication, belief about their illness, reasons 
for doses missed, and their knowledge about disease 
and medication were asked concerning to adherence. 
During study, the confidentiality of patients was 
maintained.
 Based on the reported age, the study 
participants were categorized into six groups in 
10-year increments. The data was tabulated in MS-
Excel and was analyzed by Statistical Package 
for Social Science (SPSSTM) software version 16. 
Continuous variables were expressed in terms of 
mean ± standard deviation (SD), while categorical 
variables were expressed in terms of frequency and 
percentages. Association between the variables and 
factors affecting adherence was calculated using the 
Chi-square test or Fisher-exact test whichever was 
applicable. p value less than 0.05 was considered as 
statistically significant.
RESULTS:
 A total of 91 patients were included for the 
study that met the inclusion criteria. The mean ± SD 
age of the study population was 66.4±19.9 years. 
Table 1 lists demographic characteristics of the 
participants with the chi-square test comparing each 
feature between adherent and non-adherent groups.  
 Among the participants who missed their 
medicine, reasons mentioned were medicine finished 
(38.6%), carelessness (38.6%), expenses (11.4%), 
forgot (9.1%) and travel (2.3%). The Chi-square test 
comparing the adherent  and non-adherent pattern 
in participants with different occupation (Table 1 ) 
showed that the frequency of adherent group doing 
business and services related work was statistically 
significant (p=0.013).
 Table 2 shows the lifestyle choices and 
patient history with Chi-square test compared 
between adherent and non-adherent groups. 
Although 76.9% (N=70) of the participants were not 
doing regular physical activities, the adherent group 
had significantly higher participants doing physical 
activities than the non-adherent group (p=0.039). 
When comparing the duration of diagnosis of 
disease, the adherent group consisted of statistically 
significant  participants with newly diagnosed cases 
(p=0.017).
J. Lumbini. Med. Coll. Vol 8, No 2, July-Dec 2020
Shrestha JTM, et al. Medication Adherence Pattern for Benign Prostatic Hyperplasia: A Cross-Sectional Study.
227 jlmc.edu.np
 Chi-square test comparing different factors 
affecting adherence is shown in Table 3. The 
higher proportion of participants (n=20) from the 
non-adherent group said they would stop taking 
medicine if they feel better (p=0.047) compared to 
the adherent group. The same group also said they 
have not received symptomatic relief compared to 
the adherent group (p=0.003). The adherent group 
posed that they have no fear related to medication 
compared to non-adherent group (p=0.001). A 
higher proportion of non-adherent patients said 
that medicines were not affordable when compared 
with the adherent group and the difference was 
statistically significant (p=0.047). Patients were 
also asked if they had any adverse effects with the 
medication. Drowsiness (n=8), dizziness (n=8) and 
running nose (n=3) were reported by the patients. 
However, adverse effects did not separate between 
the adherent and non-adherent group (p=0.512).
DISCUSSION: 
 In this study, we aimed to measure the 
factors affecting adherence for LUTS medication 
among BPH patients. The study showed majority 
of individuals belonged to age group above 50 
years. This finding is consistent with another study 
conducted in Italy in which majority of individuals 
belonged to age group 55-85 years.[11] Our study 
also found the prevalence of BPH in the age group 
below 50 years. The onset of BPH in this age group 
may be associated with the use of gonadotropin 
supplement therapy for undescended testes and 
the mother’s utilization of a human chorionic 
gonadotropin-containing agent during pregnancy to 
prevent spontaneous abortion.[12]
 Adherence to prescribed medication is 
crucial in the management of patients suffering from 
BPH. It is, therefore, important to understand the 
Table 1.  Demographic characteristics and adherence to treatment (N = 91)
Variables Frequency (%) Adherent Non-adherent Statistics
Age Group (years)
     30-40 2 (2.1) 1 1 X2 =2.068, df = 5, 
p = 0.840     41-50 6 (6.6) 4 2
     51-60 19 (20.9) 11 8
     61-70 29 (31.9) 16 13
     71-80 28 (30.8) 12 16
     81-90 7 (7.7) 3 4
Marital Status
     Married 88 (96.7) 47 41 X2 =3.31, df = 1,     
p = 0.068     Unmarried 2 (3.3) 0 3
Literacy
     Literate 61 (67) 34 27 X2 = 1.239, df = 1,  
p =  0.265     Illiterate 30 (33) 13 17
Ethnicity
     Brahmin 33 (36.2) 16 17 X2 =1.844, df = 4,   
p = 0.764     Chhetri 28 (30.8) 16 12
     Newar 17 (18.7) 10 7
     Mongolian 6 (6.6) 2 4
     Others 7 (7.7) 3 4
Occupation
    Farmer 29 (31.9) 10 19 X2 = 10.7, df = 3,    
p = 0.013*    Business 24 (26.4) 16 8
    Services 21 (23.0) 15 6
    Unemployed 17 (18.7) 6 11
* - Statistically significant (p < 0.05)
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Table 2.  Lifestyle variables and Adherence to treatment (N = 91).
n (%) Adherent Non adherent Statistics
Alcohol  X2 = 0.020, df = 2, 
p = 0.990Yes 21 (23.1) 11 10
Occasionally 19 (20.9) 10 9
No 51 (56.0) 26 25
Smoking X2 = 1.386, df = 5, p 
= 0.5Current 15 (16.5) 6 9
Ex-smoker 29 (31.9) 17 12
Never 47 (51.6) 24 23
Physical Activities X2 = 4.277, df = 1, p 
= 0.039*Yes 21 (23.1) 15 6
No 70 (76.9) 32 38
Duration of Diagnosis X2 = 10.255, df = 3, 
p = 0.017*<1 year 46 (50.5) 31 15
1 – 5 year 36 (39.6) 14 22
5 – 10 year 6 (6.6) 1 5
>10 year 3 (3.3) 1 2
* - Statistically significant (p < 0.05)
determinants of poor adherence which is a must to 
obtain successful treatment outcomes.[2]
 Although adherent patient have higher 
literacy number this was not statistically significant. 
Higher adherence among the patients in particular 
occupation group suggests that the occupation might 
be an important factor for adherence.
 This study found that majority of patients did 
not consume alcohol. This finding may account for 
the fact that moderate alcohol consumption decrease 
the risk of BPH as suggested by study of Parson et al., 
in older men with BPH.[13] The current study found 
that there was no clear idea of cigarette smoking 
as modifiable factors. There are conflicting data on 
the effect of cigarette smoking on serum levels of 
various sex hormones. Some studies suggested that 
cigarette smoking produces an antiestrogenic effect.
[14]
 The majority of the patients in this study 
were not involved in any types of physical activities. 
This finding is consistent with different other studies 
demonstrating that the BPH is associated with 
modifiable risk factors of cardiovascular disease and 
suggest that increased physical activity may prevent 
or attenuate the conditions.[16,17] This could be that 
the newly diagnosed participants are more likely to 
follow the prescription.
 Smoking may also affect the metabolism of 
other sex steroids such as testosterone and adrenal 
hormones, and thereby influence the incidence of 
benign and malignant growth of prostate.[15]
 Absence or reduction of symptoms of the 
illness contribute significantly to non-adherence 
to medication.[9] In contrast to this, in our study, 
a majority of patients continued taking medication 
despite reduction of symptoms. There is significant 
association observed between symptomatic relief 
and adherence to medication. The findings of current 
study also suggested higher non-adherence to 
medication in those patients who think the medication 
is not helping in the reduction of symptoms. The 
possible explanation might be that patients failed to 
realise or were not informed about the longer time 
taken for improvement in the symptoms.
 Patient’s perception about the nature and 
severity of disease influences the adherence.[18] 
In the current study, it was found that the majority 
of patients perceived that the disease can only be 
managed symptomatically but still they were non-
adherent to medication. However, some patients also 
perceived the disease as curable. Furthermore, the 
current study has shown that the majority of patient 
continued medication despite the reduction of 
symptoms which is different from the results of other 
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Table 3. Factors affecting adherence to treatment (N = 91)
n (%) Adherent Non-adherent Statistics
Knowledge about medication X2 = 1.682, df 
=1, p = 0.194  Yes 77 (84.6) 42 35
  No 14 (15.4) 5 9
Difficulty in taking medication X2 = 0.207, df = 
1, p = 0.648  Yes 9 (9.8) 4 5
  No 82 (90.2) 43 39
Patient’s perception about disease X2 = 4.52, df = 
2, p = 0.104 Curable 30 (33.0) 20 10
 Incurable 21 (23.1) 8 13
Can be only managed symptomatically 40 (43.9) 19 21
Stop taking medicine when feeling better  X2 = 3.95, df = 
1, p = 0.047*  Yes 32 (35.2) 12 20
 No 59 (64.8) 35 24
Adverse effects X2=0.431, df =1, 
p = 0.512  Yes 17 (18.7) 10 7
  No 74 (81.3) 37 37
Symptomatic relief X2 = 8.910, df = 
1, p = 0.003*  Yes 65 (71.4) 40 25
  No 26 (28.6) 7 19
Knowledge about effect if patient does not 
take medicine
X2 = 0.775, df = 
1, p = 0.379
  Yes 60 (65.9) 29 31
  No 31 (34.1) 18 13
Risk/fear regarding medication X2 = 11.61, df = 
1, p = 0.001* Yes 21 (23.1) 4 17
 No 70 (76.9) 43 27
Self-administration X2 = 0.610, df = 
1, p = 0.425 Yes 10 (11.0) 4 6
 No 81 (89.0) 43 38
Medicine affordability X2 = 3.930, df 
= 1,
    p = 0.047*
 Yes 79 (86.8) 44 35
 No 12 (13.2) 3 9
Medicine availability X2 = 3.014,   df 
= 1,
P = 0.083
 Yes 73 (80.2) 41 32
 No 18 (19.8) 6 12
Follow up  X2 = 3.463,   df 
= 1, p = 0.063 Yes 82 (90.1) 45 37
 No 9 (9.9) 2 7
Special attention from doctor X2 = 0.594, df = 
1, p = 0.441 Yes 78 (85.7) 39 39
 No 13 (14.3) 5 8
* - Statistically significant (p < 0.05)
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studies on medication adherence on various chronic 
diseases.[19] Lack of clinical symptoms might often 
be interpreted as disease free by patients resulting 
on tendency to discontinue the daily medications as 
suggested by various studies.[19]
 Risk/fear regarding the medication also 
greatly influences the adherence to the medication.
[4] In this study, the majority of patients did not 
have risk/fear regarding medication. Comparing 
to the non-adherent group, there was less risk/
fear regarding medication in the adherent group. 
This relation was statistically significant. While in 
patients who did not have such risk/fear regarding 
the medication might have helped them to achieve 
better adherence to medication. 
 In this study, adverse effects were reported 
by only 18.68% of patients. The most common side 
effects experienced by patients were drowsiness, 
dizziness and nasal congestion. It has been found that 
ejaculatory dysfunctions are more common among 
uroselective anatogonists (Tamsulosin) due to their 
concentrated action in the lower urinary tract.[5] But 
in this study such adverse effects were not reported 
by the patients. Similarly, side effects of finasteride 
like loss of libido, erectile dysfunction, ejaculatory 
dysfunctions (less common), breast engorgement and 
gynecomastia were also not reported by the patients.
[20,21] This finding supports the idea that the patients 
might have hesitated to report these adverse effects 
as it is related to sexual dysfunction. However, there 
was no significant association found between adverse 
effects and the adherence to medication. In contrast, 
non-adherence to medication due to occurrences of 
adverse effects have been observed in patients with 
type II diabetes mellitus.[22]
In this study, the majority of the adherent patients 
reported that the medicines were affordable. Taking 
medicines on their own might have led to good 
adherence among those patients though there was 
no significant association found between them. In 
contrast, the findings from previous studies have 
shown that patients who received support from their 
family members in the course of therapy had better 
adherence to medication.[23] Several studies have 
shown that patients tend to skip doses, reduce doses 
because they cannot afford to pay for medications.
[24] The present study has showed that majority 
of the non-adherent patients could not afford the 
prescribed medicines. Although, unaffordability 
of medicines might have led to non-adherences to 
medication, no significant association was found. 
Among the non-adherence patients, the majority of 
them had missed doses due to lack of affordability 
of medicine.
 In our study there were some limitations as 
the study was cross-sectional and limited to only 
one center. A multi-centered follow-up study might 
provide a better scenario of adherence. Improving 
on the margin of error with higher sample size could 
help interpret the data better.
CONCLUSION:
 We found that symptomatic relief, risk/
fear of taking medicine, stopping taking medicine 
when feeling better and affordability of medicine 
were primary reasons affecting adherence to the 
treatment. Adherence to medication is crucial to 
treat BPH. Poor adherence to medication regimen 
and to other non-drug therapy possess significant 
barrier to optimum management of BPH. This study 
provides knowledge about the adherence pattern of 
pharmacological therapy of BPH and various factors 
regarding adherence pattern influencing in BPH 
treatment. 
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